Is it too late to buy Rocket Lab stock as it soars on Q1 earnings?

Is it too late to buy Rocket Lab stock as it soars on Q1 earnings?
Wajeeh Khan
May 11, 2026, 10:03 A.M.

powered by

Invezz
RKLB buy

Buy Rocket Lab (RKLB). Q1 beat plus narrowing adjusted EBITDA losses show the business is moving from “R&D burn” to real operating leverage. The key driver is the mix shift: Space Systems is ~70% of revenue and backed by a $2.2B backlog, giving multi-year visibility. The market is also starting to price the Neutron transition and defense demand (e.g., $515M SDA contract), which supports a higher valuation floor even after a big rally.

Key Risk: Neutron slips materially (schedule or performance), breaking the path to higher-margin launch economics and causing backlog/contract momentum to stall.

Space Systems peers sell

Sell legacy aerospace/launch exposure that lacks Rocket Lab’s backlog and Space Systems mix—specifically Boeing (BA) and Northrop Grumman (NOC) relative to RKLB. The news highlights a “full-stack” moat and defense-led demand; investors will rotate toward companies with clearer, near-term revenue visibility and margin expansion, compressing multiples for slower-maturing primes.

Key Risk: Defense budgets or prime contract wins accelerate for BA/NOC enough to offset the Rocket Lab rotation and re-expand their relative growth/margin outlook.

  • Rocket Lab stock rallies on blockbuster earnings for fiscal Q1.
  • But there are ample reasons to expect more from RKLB shares.
  • Rocket Lab is currently up some 80% versus its year-to-date low.

Rocket Lab RKLB is on track to close the session about 30% higher on May 8 after reporting its financials for the first quarter that handily topped Street estimates.

In Q1, the aerospace company saw its revenue pop some 63% on a year-over-year basis to roughly $200 million – comfortably ahead of $192 million that analysts had forecast.

And while RKLB’s net loss on a GAAP basis stood at $0.09 per share, largely due to “aggressive” R&D scaling, narrowing adjusted EBITDA losses signal a clear path toward profitability.

Following the post-earnings rally, Rocket Lab shares are up an exciting 80% versus their year-to-date low.

Why Rocket Lab stock could rip higher

Investors are cheering RKLB stock primarily because of the company’s pivot toward high-margin Space Systems, which now constitute nearly 70% of the total revenue mix.

On the earnings call, CEO Peter Beck cited “super healthy demand” across the board, particularly for the firm’s end-to-end satellite solutions.

This demand is anchored by a record $2.2 billion backlog, providing a multi-year revenue runway that remains largely insulated from macroeconomic cyclicality.

The vertical integration of Motiv Space Systems “de-risks” Rocket Lab’s supply chain, forging a “full-stack” competitive moat that justifies its valuation premium over legacy aerospace incumbents.

The bull case for RKLB shares

For long-term investors, it may not be too late to build a position in Rocket Lab shares, given the imminent transition to the Neutron rocket.

Neutron challenges SpaceX’s hegemony in the lucrative mega-constellation sector, shifting RKLB unit economics from $8 million Electron launches to high-value deployments, significantly scaling its total addressable market (TAM).

Current valuations may not fully account for the “scarcity premium” of a proven, reusable launch provider.

Anchored by a $515 million SDA contract, Rocket Lab has emerged as rare, high-conviction proxy for the global defense pivot toward resilient space architecture and broader secular shift into the “Space 2.0” industrial economy.

Technicals warrant investing in Rocket Lab

RKLB shares look attractive also because the Q1 print confirms the company is no longer a high-risk venture but a maturing industrial leader.

The Nasdaq-listed firm is successfully navigating the transition from a hardware manufacturer to a high-utility service provider, a shift that historically leads to significant multiple expansion.

From a technical perspective, the stock now sits decisively above its major moving averages (MAs) – with an RSI at 67 indicating it still isn’t in the “overbought” territory.  

All in all, with the Neutron maiden flight on the horizon for late 2026, the current rally may be the baseline for a new valuation floor.

How Wall Street recommends playing RKLB

Heading into the Q1 print, analysts had a consensus “moderate buy” rating on Rocket Lab.

And while the Street-high price target of $105 no longer represents significant further upside, it’s fair to expect forward revisions after RKLB’s blockbuster first-quarter release on May 8.